Charles Harwood, Tim Derrington, John Sluis, John Fazio | GenomeWeb
BioReliance has named Charles Harwood, who currently is executive chairman, to the post of interim CEO in the wake of the departure of former CEO Tim Derrington.
 
BioReliance, which Invitrogen sold in April to Avista Capital Partners for $210 million, noted that since June three senior executives have joined the company, including David Onions as CSO, David Walker as CFO, and Darryl Goss as VP of Global Process Excellence.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.